AUROPHARMA - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 3.6
| Stock Code | AUROPHARMA | Market Cap | 80,702 Cr. | Current Price | 1,390 ₹ | High / Low | 1,460 ₹ |
| Stock P/E | 37.6 | Book Value | 369 ₹ | Dividend Yield | 0.29 % | ROCE | 10.8 % |
| ROE | 8.65 % | Face Value | 1.00 ₹ | DMA 50 | 1,314 ₹ | DMA 200 | 1,219 ₹ |
| Chg in FII Hold | 1.29 % | Chg in DII Hold | -1.84 % | PAT Qtr | 595 Cr. | PAT Prev Qtr | 581 Cr. |
| RSI | 58.2 | MACD | 33.5 | Volume | 6,22,464 | Avg Vol 1Wk | 10,70,783 |
| Low price | 1,016 ₹ | High price | 1,460 ₹ | PEG Ratio | 8.82 | Debt to equity | 0.21 |
| 52w Index | 84.2 % | Qtr Profit Var | 26.0 % | EPS | 36.7 ₹ | Industry PE | 30.1 |
📈 AUROPHARMA is trading at ₹1,390, above both its 50 DMA (₹1,314) and 200 DMA (₹1,219), confirming bullish alignment. RSI at 58.2 indicates healthy momentum without being overbought. MACD at 33.5 supports positive bias. Bollinger Bands show price moving toward the upper band, suggesting strength but with possible resistance. Current volume (6,22,464) is below the 1-week average (10,70,783), showing reduced participation despite momentum.
🔑 Short-term momentum signals: Support lies near ₹1,310–₹1,320 (50 DMA zone), resistance around ₹1,440–₹1,460 (recent high). Entry zone is closer to ₹1,310–₹1,320 on pullbacks. Exit zone should be considered near ₹1,440–₹1,460. The stock is in a trending phase with bullish bias.
✅ Positive
- Quarterly PAT growth (+26%, ₹595 Cr vs ₹581 Cr).
- EPS of ₹36.7 provides solid earnings base.
- ROCE (10.8%) and ROE (8.65%) show stable profitability.
- FII holdings increased (+1.29%), showing foreign investor confidence.
- Stock trading well above long-term averages (200 DMA).
⚠️ Limitation
- P/E (37.6) above industry average (30.1), indicating premium valuation.
- PEG ratio of 8.82 suggests overvaluation relative to growth.
- Volume below average, limiting momentum strength.
- DII holdings decreased (-1.84%), showing domestic investor caution.
📉 Company Negative News
- Valuation stretched compared to peers.
- Decline in DII holdings signals reduced domestic confidence.
📊 Company Positive News
- Quarterly profits improved.
- FII inflows support momentum.
- Technical strength above DMA levels.
🏭 Industry
- Industry P/E at 30.1 highlights sector trading at lower multiples.
- Pharma sector remains resilient with steady demand outlook.
📝 Conclusion
AUROPHARMA is trending upward with bullish technical signals supported by strong quarterly earnings. Entry near ₹1,310–₹1,320 offers favorable risk-reward, with exit around ₹1,440–₹1,460. Valuation remains stretched and volumes are below average, so momentum trades should be managed with strict stop-loss discipline.
Would you like me to extend this into a sector overlay benchmarking module so you can compare AUROPHARMA’s momentum and valuation against other pharma peers in your workflow library?